Literature DB >> 27111047

Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients.

R Greco1, M C Barbanti1, M T Lupo Stranghellini1, F Giglio1, M Morelli1, C Messina1, A Forcina1, C Oltolini2, S Piemontese1, P Scarpellini2, S Marktel1, A Assanelli1, M Carrabba1, L Vago1,3, C Corti1, M Bernardi1, J Peccatori1, F Ciceri1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27111047     DOI： 10.1038/bmt.2016.112

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

Review 2.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Authors:  Eyal Robenshtok; Anat Gafter-Gvili; Elad Goldberg; Miriam Weinberger; Moshe Yeshurun; Leonard Leibovici; Mical Paul
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

3.  Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Authors:  Corrado Girmenia; Giovanni Barosi; Franco Aversa; Andrea Bacigalupo; Tiziano Barbui; Donatella Baronciani; Alberto Bosi; Anna Candoni; Anna Locasciulli; Franco Locatelli; Francesco Menichetti; Maurizio Musso; Claudio Viscoli; Alessandro Rambaldi
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

Review 4.  Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Authors:  Corrado Girmenia; Giovanni Barosi; Alfonso Piciocchi; William Arcese; Franco Aversa; Andrea Bacigalupo; Giuseppe Bandini; Alberto Bosi; Alessandro Busca; Elio Castagnola; Desiree Caselli; Simone Cesaro; Fabio Ciceri; Anna Locasciulli; Franco Locatelli; Malgorzata Mikulska; Livio Pagano; Arcangelo Prete; Anna Maria Raiola; Alessandro Rambaldi
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-26       Impact factor: 5.742

Review 5.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

6.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.

Authors:  D Neofytos; D Horn; E Anaissie; W Steinbach; A Olyaei; J Fishman; M Pfaller; C Chang; K Webster; K Marr
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

9.  Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.

Authors:  Angela Sansone-Parsons; Gopal Krishna; Monika Martinho; Bhavna Kantesaria; Steven Gelone; Tim G Mant
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

Review 10.  Improving the safety of cell therapy with the TK-suicide gene.

Authors:  Raffaella Greco; Giacomo Oliveira; Maria Teresa Lupo Stanghellini; Luca Vago; Attilio Bondanza; Jacopo Peccatori; Nicoletta Cieri; Sarah Marktel; Sara Mastaglio; Claudio Bordignon; Chiara Bonini; Fabio Ciceri
Journal:  Front Pharmacol       Date:  2015-05-05       Impact factor: 5.810
View more
  3 in total

1.  Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation.

Authors:  Li-E Zhu; Hui-Ping Huang; Yi-Peng Cai; Yan Wang; Bao-Hua Xu; Mao-Bai Liu; Xue-Mei Wu
Journal:  Eur J Clin Pharmacol       Date:  2022-08-31       Impact factor: 3.064

2.  Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study.

Authors:  Elisabetta Xue; Francesca Lorentino; Maria Teresa Lupo Stanghellini; Fabio Giglio; Simona Piemontese; Daniela Teresa Clerici; Francesca Farina; Sara Mastaglio; Alessandro Bruno; Edoardo Campodonico; Rosamaria Nitti; Magda Marcatti; Andrea Assanelli; Consuelo Corti; Fabio Ciceri; Jacopo Peccatori; Raffaella Greco
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

3.  Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.

Authors:  Xiao Chen; Jinglin Wang; Jianger Lan; Xilin Ge; Hong Xu; Yu Zhang; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.